John Sensintaffar - Concepedia

Author

John Sensintaffar

Also Known As

J L Sensintaffar, J Sensintaffar, J.L. Sensintaffar, John L. Sensintaffar, John Lee Sensintaffar, John Sensintaffar, Sensintaffar, John L.

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Edison Pharmaceuticals (United States)Forma Therapeutics (United States)Leidos (United States)Frederick National Laboratory for Cancer Research

About

John Sensintaffar is an author at Vanderbilt University specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	17	2.8K
2	Natural Sciences	7	7	615
3	Biochemistry	3	3	245
4	Health Sciences	1	1	35
5	Public Health	1	1	224

John Sensintaffar

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Adeela Kamal, Lia Thao, John Sensintaffar, Nature Drug TargetG Protein-coupled ReceptorMedicineHsp90 ConfersMolecular Biology	2003	1.4K
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment Nicola J. Clegg, John Wongvipat, James D. Joseph, Cancer Research	2012	646
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 James D. Joseph, Nhin Lu, Jing Qian, Cancer Discovery	2013	570
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia Haley E. Ramsey, Melissa A. Fischer, Taekyu Lee, Cancer Discovery	2018	355
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts Andiliy Lai, Mehmet Kahraman, Steven P. Govek, Journal of Medicinal Chemistry Breast OncologyChemoprevention StrategyPharmacotherapyLead Compound 11LTumor Biology	2015	244
Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Joanna M. Watson, John Sensintaffar, Jonathan S. Berek, PubMed ImmunologyGynecologyPathologyCell CultureCell Proliferation	1990	224
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Karen Lundgren, Hong Zhang, John Brekken, Molecular Cancer Therapeutics	2009	168
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods Nicholas F. Pelz, Zhiguo Bian, Bin Zhao, Journal of Medicinal Chemistry Drug TargetMolecular BiologyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2016	143
Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity Srinivas Rao Kasibhatla, Kevin Hong, Marco A. Biamonte, Journal of Medicinal Chemistry Chemoprevention StrategyMolecular BiologyPharmacotherapyTumor BiologyMolecular Chaperone Protein	2007	125
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer James D. Joseph, Beatrice Darimont, Wei Zhou, eLife Diverse ModelsBreast OncologyErα SignalingCancer Cell BiologyAnti-cancer Agent	2016	117

Page 1